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Abstract
Purpose The primary objective of this study was to examine the relationship of longitudinal changes in autonomic symptom 
burden and longitudinal changes in activities of daily living (ADLs); a secondary analysis examined the impact of depressive 
symptoms in this relationship.
Methods Data were retrieved from the Parkinson’s Progression Markers Initiative (PPMI), a dataset documenting the natural 
history of newly diagnosed Parkinson’s disease (PD). The analysis focused on data from baseline, visit 6 (24 months after 
enrollment), and visit 12 (60 months after enrollment). The impact of longitudinal changes in autonomic symptom burden 
on longitudinal changes in ADLs function was examined. A secondary mediation analysis was performed to investigate 
whether longitudinal changes in depressive symptoms mediate the relationship between longitudinal changes in autonomic 
symptom burden and ADLs function.
Results Changes in autonomic symptom burden, cognitive function, depressive symptoms, and motor function all correlated 
with ADLs. Only changes in ADLs and depression were found to be associated with changes in autonomic symptom burden. 
We found that longitudinal change in autonomic symptoms was a significant predictor of change in ADLs at 24 and 60 months 
after enrollment, with the cardiovascular subscore being a major driver of this association. Mediation analysis revealed that 
the association between autonomic symptoms and ADLs is partially mediated by depressive symptoms.
Conclusions Longitudinal changes in autonomic symptoms impact ADLs function in patients with early signs of PD, both 
directly and indirectly through their impact on depressive symptoms. Future investigation into the influence of treatment of 
these symptoms on outcomes in PD is warranted.
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Introduction
Parkinson’s disease (PD) is characterized by motor and 
non-motor symptoms [1]. There is broad variability in 
clinical phenotypes and rates of progression in this dis-
ease [2–4]. How to predict outcomes for individuals with 
PD remains an important question, with healthcare and 
clinical research implications.
Many factors have been identified as influential in pre-
dicting outcomes in PD. Frequently investigated prognos-
tic factors in PD include age, disease duration, depression, 
gait impairment, and PD motor subtype [3–5]. Autonomic 
dysfunction is common in persons with PD and strongly 
impacts prognosis [6, 7]. Most studies investigating prog-
nostic predictors of PD have focused on cross-sectional 
data [2–5, 8]. Few studies have investigated the impacts of 
longitudinal changes in autonomic symptoms over time on 
functional decline in PD patients [9, 10], and none, to our 
knowledge, have been performed in a homogenous cohort 
of patients diagnosed with early stage PD over an extended 
period of time. This presents a crucial gap in knowledge 
as longitudinal changes in some clinical factors have been 
found to influence decline in health-related quality of life 
[5, 11].
We hypothesized that an increasing burden of auto-
nomic symptoms over time is negatively associated with 
changes in activities in daily living (ADLs) function in 
PD. Additionally, we hypothesized that depression would 
emerge as a driver of the change in ADLs function over 
time, as this has been demonstrated previously in different 
PD populations [12, 13]. With this aim we evaluated the 
impact and relationships of longitudinal changes in auto-
nomic symptom burden on changes in ADLs and depres-
sion scores in a prospective cohort of patients with early 
stage PD over a period of 2 and 5 years.
Methods
Subjects
The data for these analyses were obtained from the Par-
kinson’s Progression Marker Initiative (PPMI), a publicly-
available, longitudinal, prospective database of over 400 
patients with early stage PD [14]. Full information about 
the PPMI study, including inclusion/exclusion criteria, 
recruitment, sites, full list of evaluations and procedures, 
can be found at www.ppmi-info.org. Subjects underwent 
regular standardized and validated evaluations, clinical 
and cognitive assessments, imaging examinations, and bio-
logical sampling. Inclusion criteria requirements included 
symptoms of rest tremor, bradykinesia, or rigidity, and a 
diagnosis of PD for < 2 years at screening. Eligible sub-
jects were at Hoehn and Yahr stage I or II at enrollment, 
had neuroimaging findings on dopamine transporter sin-
gle-photon emission computed tomography (DaT SPECT) 
or positron-emission tomography examinations that sup-
ported the PD diagnosis, and were not taking medications 
for PD within 6 months of the baseline visit.
Of the over 400 currently enrolled subjects in PPMI, 
subject data were chosen for inclusion in the current 
analysis based on the presence of complete data at visit 
6 (24 months from baseline, N = 266), and at visit 12 
(60 months from baseline, N = 226).
 All research procedures included in PPMI were 
approved by the local Institutional Review Boards of the 
participating centers. All participants provided written 
informed consent before enrollment into the study [14].
Clinical Evaluations and Scales
All evaluations and scales used in this analysis were col-
lected as part of the PPMI protocol. Autonomic symptom 
burden was evaluated using the Scales for Outcomes in 
Parkinson’s disease—Autonomic (SCOPA-AUT) [15], 
a validated questionnaire of autonomic symptoms. The 
SCOPA-AUT includes seven questions about gastroin-
testinal function, six questions about urinary function, 
three questions about cardiovascular function, four ques-
tions about thermoregulatory function, one question about 
pupillomotor function, and three questions about sexual 
function. Higher scores indicate higher burden of auto-
nomic symptoms (score range 0–69 points).
Motor function was evaluated using the Movement Dis-
orders Society Unified Parkinson’s Disease Rating Scale 
(MDS-UPDRS) [16] part III motor score, an objective 
examination performed by a trained evaluator. All MDS-
UPDRS part III scores included in the current study were 
in the “off” medication state. A higher MDS-UPDRS score 
(range 7–86 points) indicates a higher degree of motor dys-
function. ADLs function was evaluated with the Schwab 
and England (S&E) Activities of Daily Living (ADLs) 
scale, in which a higher value indicates better function 
(score range 10–100%). No additional measures of ADLs 
function or measures of quality of life were included in the 
PPMI study. Depression was measured using the Geriatric 
Depression Scale (GDS), in which higher score indicates a 
higher burden of depressive symptoms (score range 0–15 
points) [17]. Cognitive function was assessed using the 
Montreal Cognitive Assessment (MoCA) screening tool, 
in which a lower score indicates worse cognitive function 
[18].
Outcome Measures and Statistical Analysis
The primary independent variable in this analysis was 
the change in SCOPA-AUT score from baseline to visit 6 
(month 24), and from baseline to visit 12 (month 60), and 
the primary dependent variable was change in S&E score 
over this same time period. Secondary endpoints were lon-
gitudinal changes in the GDS [17], MoCA [18], and the 
MDS-UPDRS part III [16]. Orthostatic hypotension (OH) 
was defined as a reduction in blood pressure of 20 mmHg 
systolic, or 10 mmHg diastolic, with changing from the 
supine to standing position, as reported in the PPMI data-
base. Statistical analyses were performed using SAS 9.4 sta-
tistical software (SAS Institute Inc., Cary, NC, USA) and the 
PROCESS macro developed by Hayes [19]. Means, standard 
deviations, and ranges were obtained for demographic vari-
ables and for all scales included in the analysis (Table 1). 
Two-sample t tests were used to compare means of continu-
ous clinical variables at different visits, and the Chi-square 
test was performed to compare categorical variables in dif-
ferent visits. The Spearman correlation coefficient was used 
to evaluate associations between clinical variables. Simple 
linear regression analysis was utilized to evaluate the impact 
of longitudinal changes in SCOPA-AUT on longitudinal 
changes in ADLs scores. Mediation analysis was performed 
to evaluate whether depression, as measured by the GDS, 
may mediate the association between autonomic symptom 
burden, as measured by the SCOPA-AUT, and ability to 
perform ADLs, as measured by the S&E scale. In order to 
test the statistical significance of the mediation, or indirect 
effects, 95% confidence intervals (CIs) were established by 
using a bootstrapping approach with 5000 samples. Sta-
tistical significance in these tests was obtained whenever 
the 95% CI fell outside the value of zero. To test whether 
this mediation model was moderated by severity of motor 
symptoms in this cohort, a moderated mediation model was 
used to investigate whether the strength and/or direction of 
the proposed indirect effect of depressive symptoms was 
contingent upon subject’s severity of motor dysfunction, as 
assessed by MDS-UPDRS part III scores.
Results
We analyzed data from all 266 subjects in the PPMI database 
who had data available for the clinical variables of inter-
est at visit 6 (24 months), and all 226 subjects who had 
data available for the clinical variables of interest at visit 
12 (60 months). Between baseline and visit 6, and baseline 
and visit 12, there was a decline in the S&E, SCOPA-AUT, 
MoCA, GDS, and MDS-UPDRS III scores (Table 1). Demo-
graphic data and descriptive statistics for the clinical vari-
ables are summarized in Table 1.
Longitudinal increases in the SCOPA-AUT score from 
baseline were significantly associated with worsening S&E 
score at visit 12 (r = − 0.170, p = 0.010) but not visit 6 
(r = − 0.095, p = 0.124) (Fig. 1). Increasing SCOPA-AUT 
score was also associated with increasing GDS score at 
visit 6 (r = 0.203, p = 0.001) but not at visit 12 (r = 0.126, 
p = 0.058). Correlations between S&E, SCOPA-AUT, GDS, 
MDS-UPDRS part III, and MoCA scores, and age at visit 6 
and visit 12 are presented in Fig. 1.
Table 1  Demographics and 
clinical variables of subjects 
with Parkinson’s disease at 
baseline, visit 6, and visit 12
All values are presented as the mean with the standard deviation (SD) in parenthesis, with the exception of 
number (%) of males in study
GDS Geriatric Depression Scale, MoCA Montreal Cognitive Assessment, MDS-UPDRS 3 Movement Disor-
ders Society Unified Parkinson’s Disease Rating Scale part 3 (motor examination), S&E ADLs Schwab and 
England Activities of Daily Living, SCOPA-AUT Scale for Outcomes in Parkinson’s disease for Autonomic 
Symptoms
*p < 0.01 difference between this value and baseline value; **p < 0.001 difference between this value and
baseline value
Demographics and clinical variables Baseline (N = 315) Visit 6 (24 months 
from baseline) 
(N = 266)
Visit 12 (60 months 
from baseline) 
(N = 226)
 Male, N (%) 230 (73.0%) 180 (67.7%) 152 (67.3%)
Age (years) 62.5 (9.8)
Disease duration (years) 0.6 (0.7)
S&E ADLs scale score 92.8 (5.8) 88.5 (7.7)** 84.93 (10.0)**
SCOPA-AUT score 9.3 (6.1) 11.3 (6.9)** 13.1 (7.9)**
MoCA scale score 26.9 (2.4) 26.0 (3.2)** 26.6 (3.3)**
MDS-UPDRS part III score 21.2 (8.9) 27.4 (11.5)** 31.0 (11.8)**
GDS score 2.4 (2.7) 2.7 (2.8)** 2.7 (2.7)**
Hoehn and Yahr stage 1.5 (0.5) 1.8 (0.6)** 2.0 (0.4)*
We then investigated whether taking medication for 
depression or medications that lower blood pressure could 
influence our results. Subjects were categorized as “taking” 
or “not taking” medications for depression or medications 
that lower blood pressure, respectively. There was a sig-
nificant association between depression medication utiliza-
tion and SCOPA-AUT score at baseline, visit 6, and visit 
12 (r = 0.196, p = 0.003; r = 0.136, p = 0.026; and r = 0.169, 
p = 0.011, respectively). There were correlations between 
utilization of medication for depression and depression 
scores at baseline, visit 6, and visit 12 (r = 0.231, p < 0.001; 
r = 0.334, p < 0.001; r = 0.227, p < 0.001, respectively). 
There was no association between SCOPA-AUT scores and 
utilization of medications that lower blood pressure at base-
line, visit 6, or visit 12.
Longitudinal changes in SCOPA-AUT scores from base-
line significantly predicted worsening in S&E scores at 
visit 6 (24 months) (ß = − 0.21, p = 0.015) and at visit 12 
(60 months) (ß = − 0.40, p = 0.0001), after adjusting for age. 
Changes in the SCOPA-AUT score further predicted worsen-
ing in GDS score at visit 6 (ß = 0.10, p < 0.001) and at visit 
12 (ß = 0.08, p = 0.012), but theydid not predict changes in 
MoCA or MDS-UPDRS part III scores (Table 2).
To understand whether depression medication usage 
confounds the relationship between longitudinal change 
in SCOPA-AUT scores and longitudinal change in ADLs 
scores, the regression analysis was repeated control-
ling for depression medication usage. The results at visit 
6 (ß = −  0.200, p = 0.018) and at visit 12 (ß = −  0.39, 
p = 0.0002) were comparable.
In a subanalysis, we investigated the impact of longi-
tudinal changes in SCOPA-AUT subscores on decline in 
S&E scores. Mean SCOPA-AUT subscores and preva-
lence of symptoms at each visit are presented in Elec-
tronic Supplementary Material (ESM) Table  1; these 
are similar to previous findings in this cohort [20]. We 
found that an increase in the cardiovascular subscore of 
SCOPA-AUT was the strongest predictor of a decline in 
S&E score at visit 6 (ß = − 0.92, p  = 0.031) and in fact 
was the only subscore that reached statistical significance. 
There were no significant SCOPA-AUT subscore predic-
tors of ADLs function at visit 12 (see ESM Table 2). The 
Fig. 1  Associations of longitudinal changes in clinical variables 
between baseline and visit 6 (a; 24 months from baseline), and 
between baseline and visit 12 (b; 60 months from baseline). Values 
are expressed as the Spearman correlation coefficient. Asterisk indi-
cates a signficant difference at p < 0.05. GDS Geriatric Depression 
Scale, MDS-UPDRS3 Movement Disorders Society Unified Parkin-
son’s Disease Rating Scale part III (motor examination), MoCA Mon-
treal Cognitive Assessment scale, SCOPA-AUT Scale for Outcomes in 
Parkinson’s disease for Autonomic Symptoms, S E Schwab and Eng-
land Activities of Daily Living scale
Table 2  Effects of longitudinal changes in Scale for Outcomes in 
Parkinson’s disease for Autonomic Symptoms scores on clinical vari-
ables
Values adjusted for subject age at baseline




β p value β p value
S&E ADLs score − 0.21 0.015 − 0.40  < 0.001
GDS score 0.10  < 0.001 0.08 0.012
MoCA score − 0.06 0.068 0.00 0.976
MDS-UPDRS part III score 0.17 0.115 0.12 0.345
SCOPA-AUT cardiovascular subscore was similarly the 
strongest predictor of an increase in GDS score at visit 6 
(ß = 0.49, p < 0.001) and visit 12 (ß = 0.38, p = 0.024) (see 
ESM Table 3). There were no significant changes in ther-
moregulatory, pupilomotor, or sexual subscores between 
the baseline visit, visit 6, or visit 12.
We used mediation analysis, with bootstrapping-based 
assessment of confidence intervals, to investigate whether 
the relationship between autonomic symptom burden 
and ADLs function is mediated by depressive symptoms 
(Fig.  2). This analysis revealed a significant indirect 
effect of SCOPA-AUT scores on S&E scores through the 
GDS scores at visit 12 (ß = − 0.064, 95% CI − 0.181 to 
− 0.001) but not at visit 6 (ß = − 0.033, 95% CI − 0.083
to 0.007) (Fig. 2), indicating that the effects of autonomic
symptoms on functional decline are partially mediated
by their contribution to depressive symptoms. Similar
to the analysis reported above, the indirect effect of the
cardiovascular subscore of SCOPA-AUT was a strong
predictor of decline in ADLs at visit 12 (ß = -0.407, 95% 
CI − 0.946 to −  0.064) but not at visit 6 (ß = − 0.177, 
95% CI − 0.444 to − 0.043). We further tested whether
this mediation model was moderated by the severity of
motor symptoms, as measured by the MDS-UPDRS part
III, but this moderated mediation was not significant at
visit 6 or visit 12.
In a secondary analysis, we explored the associations 
between the presence of OH and other clinical variables. 
In total, there were 42 study participants with OH at base-
line (13.4%), 49 at visit 6 (18.7%), and 42 at visit 12 
(18.58%). We found no significant association between 
the presence of OH and SCOPA-AUT scores at baseline, 
but there was a significant correlation between these 
two variables at visit 6 and visit 12 (r = 0.16, p = 0.008; 
r = 0.26, p < 0.001, respectively). Associations between 
presence of OH and other variables are presented in ESM 
Table 4.
Discussion
Our main finding is that longitudinal changes in autonomic 
symptom burden are associated with a worsening in ADLs in 
patients with early stage PD over an extended period of time. 
Few prior studies have investigated this relationship, and 
none over the time period included in this study. Although 
associations between autonomic symptoms and depression, 
and autonomic symptoms and ADLs, have been previously 
shown, the mediating effect of depression on the association 
between longitudinal changes in autonomic symptoms and 
ADLs had not been investigated before. In this regard we 
found that the negative impact of autonomic symptoms on 
function in PD is partially due to the impact of autonomic 
symptoms on depressive symptoms.
There have been few prior studies investigating longitu-
dinal changes in autonomic symptoms and their impact on 
outcomes in persons with PD [9, 10]. Visser et al. found 
that though baseline autonomic symptoms seemed to impact 
decline in health-related quality of life (HR-QOL), changes 
in autonomic symptom burden over 2 years did not seem 
to have a significant impact on this variable [9]. In their 
study, the average disease duration of participants at base-
line was > 10 years (standard deviation 6.5 years), and the 
mean change in the SCOPA-AUT score over the 2-year time 
period of the study was very small (1.1 points) [9], smaller 
than the change found in the current study. The lack of a 
significant result in this study may be due to these differ-
ences in variability [9]. Furthermore, it is likely that decline 
in HR-QOL is impacted by changes in SCOPA-AUT differ-
ently in different stages of PD; thus, the effects of changing 
SCOPA-AUT scores on HR-QOL were likely masked by the 
heterogeneity of this cohort with respect to disease duration. 
In another study, Merola et al. found a significant impact of 
change in SCOPA-AUT score and decline in ADLs score 
over a time period of 1 year, with gastrointestinal symptom 
change and cardiovascular symptom change in particular 
Fig. 2  Depressive symptoms mediate the longitudinal effects of auto-
nomic symptoms on activities of daily living (ADLs) function at visit 
12 but not at visit 6. a Visit 6, b visit 12. Path a indicates the direct 
effect of autonomic symptoms on depressive symptoms. Path b indi-
cates the direct effect of depressive symptoms on ADLs function. 
Path c′ indicates the indirect effect of autonomic symptoms on ADLs 
function. S&E  Schwab and England Activities of Daily Living scale
being the primary drivers of this association [10]; this result 
supports our findings. This study had similar heterogene-
ity in the cohort with regards to disease duration as that 
of Visser et al. [9], with a mean and range in disease dura-
tion of > 10 years and 1–26 years, respectively, and patients 
were followed for 12 months [10]. Though disease duration 
was adjusted for, there may have been limited SCOPA-AUT 
change over that time period to mask the association. The 
novelty of the current study is that the investigation was 
conducted in a homogenous cohort with regards to disease 
duration, i.e., early stage of PD (within 2 years of diagnosis), 
over a much longer period of time. Our study adds to the 
existing literature by demonstrating the significant impact of 
changes in autonomic symptom burden on decline in ADLs 
scores in early PD.
In a subanalysis, we investigated the associations between 
the presence of OH and other clinical variables. We found 
statistically significant associations between the presence 
of OH and SCOPA-AUT and ADL scores at visit 6, and 
between presence of OH and SCOPA-AUT and GDS scores 
at visit 12. There were no statistically significant associa-
tions between OH and ADL scores, SCOPA-AUT scores, or 
GDS scores at baseline. The inconsistency in these results 
may be due to insufficient power of the study. OH is uncom-
mon in the early stages of PD, which is reflected in the low 
frequencies observed in this cohort.
Our study again demonstrates the association between 
depression and decline in ADLs function, which has been 
investigated previously. However few studies have investi-
gated the role of longitudinal changes in depressive symp-
toms on ADLs function or quality of life [5, 11–13]. Our 
study additionally found that longitudinal changes in depres-
sion act as a partial mediator in the association between 
changes in autonomic symptoms and decline in ADLs. Thus, 
we propose a model in which both autonomic symptoms and 
depression have direct impacts on ADLs function, in addi-
tion to the indirect mediation effect (Fig. 2). This finding 
indicates that depression should not be treated independently 
of autonomic symptoms in persons with PD.
Autonomic dysfunction has previously been implicated 
in the development of depression PD [21]. In support of the 
mediation effects found in the current study, it is likely that 
depression and autonomic dysfunction in PD, particularly 
cardiovascular autonomic dysfunction, share a common 
neurochemical substrate. Depression in PD patients may 
be attributable to a loss of dopaminergic and noradrenergic 
innervation in the brain [22], and treatment of depression in 
these presons may be more effective with agents that also 
block norepinephrine re-uptake [23]. Similarly, noradrener-
gic failure has been found to correlate with cardiovascular 
autonomic dysfunction in PD [24]. Distinct neural substrates 
of autonomic dysfunction in PD, particularly the hypothala-
mus, are being identified [25, 26], which includes structures 
with functions overlapping with depression networks [27, 
28]. Noradrenergic dysfunction has also been implicated in 
REM sleep behavior disorder and cognitive decline in PD 
patients [29, 30]. Clustering of these symptoms may indicate 
the existence of a “malignant phenotype” in PD [30].
Controlling for depression medication usage in the asso-
ciation between longitudinal changes in autonomic symp-
tom burden and longitudinal changes in ADLs scores did 
not significantly alter this relationship. However, we did 
find significant associations between severity of depressive 
symptoms and utilization of medications for depression. It 
is unclear whether this variable simply reflects the severity 
of depression rather than being an independent influence on 
autonomic symptom burden. Future prospective studies may 
be better able to differentiate these effects.
A limitation of this study is that objective measures of 
autonomic dysfunction, apart from orthostatic vital signs, 
were not available in this dataset. Previous studies have 
found erratic correlations between subjective autonomic 
symptom questionnaire scores and physiologic autonomic 
function testing results [31], though both subjective and 
objective autonomic symptoms correlate with disease 
severity [31]. Conversely, a correlation between abnor-
mal autonomic testing results and frequency of autonomic 
symptoms in PD has been demonstrated [32]. Despite there 
being a lack of consensus regarding correlations between 
autonomic symptoms and autonomic function in PD, both 
subjective and objective measures of autonomic dysfunc-
tion in PD appear to have a negative impact on ADL func-
tion [33]. In the current study, associations were identified 
between autonomic symptom burden and the presence of 
orthostatic hypotension at visit 6 and visit 12, but not at 
baseline, though the lack of power in this analysis limits 
formal conclusions.
The importance of investigating longitudinal changes 
in clinical factors, as opposed to cross-sectional data, and 
their impact on decline in ADLs in PD patients is that there 
emerges a role for intervention. Baseline characteristics are 
dependent on the point in time when those data are collected 
and are, therefore, less meaningful with regards to a role for 
intervention. In this study, we chose to focus on interven-
able characteristics, such as changes in autonomic symptom 
burden and depression, rather than on non-intervenable char-
acteristics, such as age and disease duration, as our vari-
ables of interest. Specifically, it appears that cardiovascular 
autonomic symptoms are a major driver of this association. 
It is unclear whether interventions to improve autonomic 
symptoms in PD would improve outcomes; this would be an 
important area for further research. Furthermore, the impact 
of treating autonomic symptoms on the severity of depres-
sive symptoms, and vice versa, deserve further examination. 
Future studies would benefit from evaluating both subjective 
and objective measures of autonomic dysfunction, as well 
as incorporating outcome measures evaluating quality of life 
in persons with PD.
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